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72% received disability payments. In the UK, the annual costs of
unemployment and suicide were £1510 million and £179
million, respectively. The estimated UK national cost of bipolar
disorder was €4.59 billion, with hospitalization during acute
episodes representing the largest component. CONCLUSIONS:
Bipolar disorder is a major and underestimated health problem in
Europe. A number of issues impact on the burden of the disease,
such as comorbidities, suicide, early death, unemployment or
underemployment. Direct costs of bipolar disorder are mainly
associated with hospitalization during acute episodes. Indirect
costs are a major contributor to the disease burden but are not
always recognized in research studies. Supported by funding
from AstraZeneca Pharmaceuticals LP.
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OBJECTIVES: While pharmacological hepatic interaction
mechanisms for antipsychotics are largely known, there is little
research so far on the prevalence of potential interactions with
other substances. The objective of the present study is to estimate
the annual prevalence of potential pharmacokinetic drug-drug
interactions (DDIs) between antipsychotic and non-antipsychotic
therapies in patients with schizophrenia. METHODS: A retro-
spective analysis of drug prescriptions for patients treated for
schizophrenia (ICD-10 codes F20–F29) was performed using the
German IMS Disease Analyzer data for psychiatrists for 2007.
These data originate from electronic medical records from a
representative panel of German psychiatrists, and include drug
prescriptions and medical diagnoses. Potential antipsychotic
drug-drug interactions based on cytochrome P450 metabolism
(1A2, 2D6, 3A4, and 3A pathways) for antipsychotics and cor-
responding interacting drugs (pathway inducers and inhibitors)
were identiﬁed based on literature and drug information
resources. A potential DDI was identiﬁed when combinations
known to interact had 20 or more days of overlap, determined by
prescription dates, dosing information and pack size. Incidence
of overlap was calculated by antipsychotic, metabolic pathway
and interaction mechanism. RESULTS: A total of 5449 patients
received an atypical antipsychotic. The most frequent interaction
mechanisms were inhibition of CYP2D6 and of CYP3A4:
between 38% and 45% of the patients treated with atypicals had
a 20 day-overlap with inhibitors of CYP2D6, and 17% to 26%
with CYP3A4-Inhibitors. Potential interactions were most com-
monly associated with antidepressants. CONCLUSIONS: The
risk of potential DDI in schizophrenia patients treated with
antipsychotics in Germany is common, mainly due to concomi-
tant prescription of antipsychotics and antidepressants. The
reported estimates are based on real world data for psychiatrists
in Germany, and are conservative, since drugs prescribed by
other physicians or bought over the counter could not be taken
into account.
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OBJECTIVES: In 2002, the National Institute for Health and
Clinical Excellence (NICE) highlighted extrapyramidal symp-
toms (EPS), sexual dysfunction, sedation, and weight gain, as the
outcomes considered by patients taking atypical antipsychotics
to be the most troublesome. This research was designed to
compare the tolerability of the new extended release quetiapine
to the existing quetiapine immediate release formulation on these
outcomes in addition to orthostatic hypotension, which could be
a signiﬁcant cause of morbidity. METHODS: Systematic review
of CENTRAL, BIOSIS, EMBASE and MEDLINE for randomised
controlled trials (RCTs) in patients with acute bipolar disorder
treated with quetiapine was conducted in May 2008. Meta-
analyses of quetiapine vs placebo used a random effects model.
The results from the individual meta-analyses formed the basis of
an adjusted indirect comparison of the two quetiapine formula-
tions using placebo as a common comparator. Summary effect
estimate for each outcome was calculated as relative risk (RR)
with 95% conﬁdence interval (95% CI) where RR < 1 favoured
extended release and RR > 1 favoured immediate release.
RESULTS: Of the 331 papers initially identiﬁed in the literature
search, 5 RCTs compared quetiapine with placebo with a
common daily dose of 300mg (4 RCTs immediate release and 1
RCT extended release). Adjusted indirect comparison identiﬁed
no signiﬁcant differences between the two formulations of que-
tiapine in the outcomes assessed. Individual results were as
follows: EPS RR0.34 (95% CI: 0.04 to 12.07); orthostatic
hypotension RR1.81 (95% CI: 0.19 to 57.84); prolactin RR1.92
(95%CI: 0.11 to 123.24); sedation RR1.09 (95%CI: 0.51 to
6.29); weight gain RR0.26 (95% CI: 0.05 to 6.86). CONCLU-
SIONS: This adjusted indirect comparison of ﬁve placebo-
controlled clinical trials suggests that the tolerability proﬁle of
extended release quetiapine is consistent with that of the imme-
diate release formulation. Further research will need to be con-
ducted to determine if these results are replicated in real-life
clinical practice.
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OBJECTIVES: To compare the tolerability proﬁles of atypical
antipsychotics assessed in randomised controlled trials (RCTs).
METHODS: Systematic review of BIOSIS, CENTRAL,
EMBASE, MEDLINE, PsycINFO for RCTs comparing two or
more atypical antipsychotics (aripiprazole—ARI, olanzapine—
OLZ, quetiapine—QTP, risperidone—RSD, ziprasidone—ZPD).
Searching was restricted to English-language publications and
was completed in December 2007. Data were extracted on the
following outcomes: anxiety or depression, bodily anxiety or
restlessness, dizziness or nausea, extrapyramidal symptoms
(EPS), sexual dysfunction, stiffness or tremor, tiredness or weak-
ness, weight gain. Data were recalculated if not presented in an
intention-to-treat format. Mixed treatment comparisons were
conducted by Bayesian Markov Chain Monte Carlo simulation
using uninformed priors. Summary effect estimates (Odds Ratios
[OR], 95% credible intervals [95%CrI]) were calculated com-
pared to RSD. RESULTS: Of the 2963 papers identiﬁed in the
literature search, 50 were found to provide data on 48 RCTs
comparing two or more atypical antipsychotics. The results pre-
sented a wide spectrum of tolerability among the atypical antip-
sychotics with no single treatment being identiﬁed as consistently
better tolerated than all other. The outcomes that could be con-
sidered statistically signiﬁcant at the 5% level were: decrease in
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bodily anxiety or restlessness with QTP (OR 0.506, 95%CrI:
0.290, 0.789), decrease in EPS with QTP (OR 0.441, 95%CrI:
0.129, 0.910), increase in weight gain with OLZ (OR 2.139,
95%CrI: 1.764, 2.626), and decrease in weight gain with ZPD
(OR 0.466, 95%CrI: 0.317, 0.657). CONCLUSIONS: The
results of this systematic review paint a complex picture akin to
the nature of schizophrenia and bipolar disorder, reinforcing the
importance of treatment choice. To achieve optimal outcomes,
physicians need to consider efﬁcacy and tolerability together with
the patient’s psychiatric history, preferences and values when
making treatment decisions.
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OBJECTIVES: In 2002, the National Institute for Health and
Clinical Excellence (NICE) highlighted extrapyramidal symp-
toms (EPS), sexual dysfunction, sedation, and weight gain, as
the outcomes considered by patients taking atypical antipsy-
chotics to be the most troublesome. This research was designed
to compare the tolerability of the new extended release que-
tiapine to the existing quetiapine immediate release formulation
on these outcomes in addition to orthostatic hypotension,
which could be a signiﬁcant cause of morbidity. METHODS: A
meta-analysis of the four regulatory randomised controlled
trials (Study 041, 133, 132 and 146) comparing quetiapine
extended release with the immediate release formulation using
a ﬁxed effect model. Summary effect estimate was calculated as
relative risk (RR) with 95% conﬁdence interval (95% CI)
where RR < 1 favours extended release and RR > 1 favours
immediate release. All comparisons were conducted on a
mg-for-mg basis (300 mg, 400 mg 600 mg and 800 mg) for the
two formulations. Statistical heterogeneity was tested for using
a chi-square test. A sensitivity analysis was conducted using a
random effects model. RESULTS: All outcomes were measured
consistently in the trials included in the analyses. There were no
signiﬁcant differences between the two formulations of quetiap-
ine for any outcomes assessed. Individual results were as
follows: EPS RR 1.067 (95%CI: 0.694 to 1.641; p = 0.767);
orthostatic hypotension RR 1.089 (95%CI: 0.744 to 1.595;
p = 0.661); sedation RR 0.781 (95%CI: 0.569 to 1.073;
p = 0.128); weight gain RR 0.784 (95%CI: 0.521 to 1.180; p =
0.244); prolactin RR 0.708 (95%CI: 0.465 to 1.077; p =
0.107). Signiﬁcant heterogeneity was not detected in any com-
parison (all p > 0.42) and the effect of using a random effects
model made no difference to the summary effect estimates.
CONCLUSIONS: The meta-analysis suggests that the tolerabil-
ity proﬁle of extended release quetiapine is consistent with that
of the immediate release formulation.
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OBJECTIVES: By testing a methodology that combines labelled
and non-labelled public expenditure, this report aims to produce
ﬁrst estimates of the amounts European governments spend on
the illegal drug problem. METHODS: The European Informa-
tion Network on Drugs and Drug Addiction (REITOX) was
asked to list any budgeted labelled drug-related fund found after
reviewing government budgets for the year 2005 in 30 countries.
In order to ensure consistency in comparing ﬁgures over time and
across countries, labelled expenditure was classiﬁed according to
the International Classiﬁcation of the Functions of Government
(COFOG). Since not all drug-related expenditure is identiﬁed as
such in budgets, modelling approaches were used to estimate
the amount embedded in other programmes and interventions.
Non-labelled drug-related expenditure was obtained by using a
top-down costing approach to estimate the proportion of expen-
diture causally attributable to drug use. Wherever possible,
REITOX explored feasible deﬁnitions of ‘attributable propor-
tions’ for estimating non-labelled drug-related expenditure under
two COFOG functions: public order and safety and health.
RESULTS: On the whole, countries have a considerable amount
of quality information available on this type of costs, although
calculating the non-labelled constituent is often an arduous task.
Estimates from reporting countries extrapolated to European
level arrived at a total cost of drug-related public expenditure in
2005 of €34 billion, which is equivalent to 0.3% of the sum of
the GDP of all of the countries. This represents an average
expenditure of €60 per European citizen per year. CONCLU-
SIONS: Whilst such ﬁgures should still be used with caution (the
methodology still needs reﬁning and country data is in no way
uniform), one observation the report makes is that the disburse-
ments identiﬁed mainly refer to public expenditure made at
central government level. The future inclusion of sub-national
government expenditure will certainly increase the amounts of
public expenditure estimated.
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Cost containment in Germany is to a large extent regulated by
ﬁxed doctor’s budgets (Richtgrößen) for treatment of patients in
statutory health insurance (SHI). With Olanzapine (OLA) and
oral Risperidone (RIS) two of the most often used second gen-
eration antipsychotics (SGA) lost patent in 2007. Generic substi-
tution could lead to signiﬁcant cost savings. OBJECTIVES: Aim
of this database analysis was to estimate the budget impact of
prescribing generic OLA and RIS and to evaluate the potential
for a more individualized therapy in schizophrenia without
exceeding budgets. METHODS: Using the IMS Disease Analyzer
based on the electronic medical records of 112 psychiatrist prac-
tices in Germany, a retrospective analysis of drug expenditures
for schizophrenia was conducted. As reference data from QIV
2007 were used. Budget impact was then estimated based on a
scenario assuming generic prices being 20% (RIS) or 30% (OLA)
of original and an overall generic patient share of 80%.
RESULTS: Data of 93.844 SHI-insured patients were analyzed,
65.028 of those with drug prescriptions in QIV 2007. Mean drug
expenditures per patient in QIV 2007 was €195.52.7% of drug
expenditures of psychiatrists could be explained by SGA pre-
scriptions. A total of 55.1% of their patients treated with SGA
received either RIS or OLA. This corresponded to 49.3% of costs
for SGA. The estimated budget impact according to the scenario
is a cost saving of 25.6% of the drug expenditure for SGA.
CONCLUSIONS: Especially in schizophrenia there is a need for
therapy optimization according to current treatment guidelines
and as also aspired by payers. As the data show, there is a
signiﬁcant cost saving potential from use of generic SGA. These
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